Morgan Stanley Assembly Biosciences, Inc. Transaction History

Morgan Stanley

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.65 - $1.25 $9,142 - $17,581	-14,065 Reduced 31.45%	30,660 $25,000
Q3 2023 Nov 15, 2023	SELL	$0.87 - $1.13 $59 - $76	-68 Reduced 0.15%	44,725 $39,000
Q2 2023 Aug 14, 2023	BUY	$0.81 - $1.15 $295 - $419	365 Added 0.82%	44,793 $51,000
Q1 2023 May 15, 2023	BUY	$0.8 - $1.74 $10,440 - $22,707	13,050 Added 41.59%	44,428 $37,000
Q4 2022 Feb 14, 2023	SELL	$1.09 - $1.52 $25,471 - $35,519	-23,368 Reduced 42.68%	31,378 $40,000

Q3 2022 Nov 14, 2022	SELL	$1.7 - $2.34 $22,980 - $31,632	-13,518 Reduced 19.8%	54,746 $89,000
Q2 2022 Oct 27, 2022	BUY	$1.35 - $2.29 $3,407 - $5,779	2,524 Added 3.84%	68,264 $143,000
Q2 2022 Aug 15, 2022	BUY	$1.35 - $2.29 $3,407 - $5,779	2,524 Added 3.84%	68,264 $143,000
Q1 2022 Oct 27, 2022	SELL	$1.46 - $2.45 $3,685 - $6,183	-2,524 Reduced 3.7%	65,740 $135,000
Q1 2022 May 13, 2022	SELL	$1.46 - $2.45 $602 - $1,011	-413 Reduced 0.62%	65,740 $135,000
Q4 2021 Feb 14, 2022	BUY	$2.13 - $3.46 $19,519 - $31,707	9,164 Added 16.08%	66,153 $155,000
Q3 2021 Nov 15, 2021	BUY	$3.14 - $3.9 $178,945 - $222,257	56,989 New	56,989 $198,000

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $665M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.